ישראל - עברית - Ministry of Health

dexcel ltd, israel - iomeprol - תמיסה להזרקה - iomeprol 612.4 mg/ml - iomeprol - iomeprol - contrast medium for diagnostic radiology. intravenous urography ( in adults and paediatrics), peripheral phlebography, ct (brain and body), cavernosography, intravenous dsa, conventional angiography, intraarterial dsa, angiocardiography (in adults and paediatrics), conventional selective coronary arteriography, interventional coronary arteriography, ercp, arthrography, hysterosalpingography, fistulography, discography, galactography, chloangiography, dacryocystography, sialography, retrograde urethrography, retrograde pyelo-ureterography.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - iomeprol - תמיסה להזרקה - iomeprol 714.4 mg/ml - watersoluble, nephrotropic, low osmolar x-ray contrast media - contrast medium for diagnostic radiography. intravenous urography (in adults and pediatrics), ct (body), intravenous dsa, conventional angiography, intraarterial dsa, angiocardiography (in adults and pediatrics), conventional selective coronary arteriography, interventional coronary arteriography , arthrography, hysterosalpingography, fistulography, galactography, retrograde chloangiography, dacryocystography, sialography.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - iomeprol - תמיסה להזרקה - iomeprol 816.5 mg/ml - watersoluble, nephrotropic, low osmolar x-ray contrast media - contrast medium for diagnostic radiography. intravenous urography (in adults ,including those with renal impairment or diabetes), ct (body), conventional angiography, intraarterial dsa, angiocardiography (in adults and pediatrics), conventional selective coronary arteriography, interventional coronary , arthrography, fistulography, galactography, dacryocystography, sialography.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - ethinylestradiol 0.01 mg; ethinylestradiol 0.03 mg - tablets - ethinylestradiol - seasonique is indicated for use by women to prevent pregnancy.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - ethinylestradiol 0.01 mg; ethinylestradiol 0.02 mg - tablets - ethinylestradiol - seasonique l is indicated for use by women to prevent pregnancy.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - tibolone - טבליה - tibolone 2.5 mg - tibolone - tibolone - complaints resulting from the natural or artificial menopause. prevention of osteoporosis in estrogen deficiency states. treatment of estrogen deficiency symptoms in postmenopausal women.

ישראל - עברית - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m